HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · CagriSema (Cagrilintide + Semaglutide)
GLP-1 / amylin blend · research-use
CagriSema blend OEM supply.
Research-grade cagrilintide + semaglutide co-formulated vials for B2B buyers and private-label brands, shipped with per-component COA.
!
Research use — supplied as research peptides; buyers confirm local compliance
On 2026-04-30 the FDA proposed removing GLP-1 medications from the 503B bulks list. Pending finalization, US 503B facilities cannot compound these from bulk substances. Pepti positions GLP-1 compounds for research and private-label brand evaluation worldwide. Read the GLP-1 2026 update →
CagriSema (CagriliHPLC ≥ 98%MS confirmed5mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | CagriSema (Cagrilintide + Semaglutide) |
|---|---|
| Class | Blends |
| Form | Lyophilized powder, sterile glass vial |
| Purity target | ≥ 98% by HPLC |
| Vial formats | 5mg / 20mg |
| Documentation | COA + HPLC + MS, batch lot file where available |
| Distribution scope | Research use, worldwide |
| Storage | Lyophilized powder: store at -20°C, protected from light and moisture; typically stable 24+ months. After reconstitution, hold at 2-8°C and use within the validated study window. Ships cold-chain with ice packs. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 100 vials | 5–10 days |
| Production lot | 500–2,000 vials | 14–21 days |
| OEM repeat | 2,000+ vials | 21–28 days, scheduled |
CagriSema is a fixed-dose research blend co-formulating the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide in a single vial.
Documentation
Batch documentation support for CagriSema (Cagrilintide + Semaglutide) lots.
COA / HPLC / MS document support where available. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the CagriSema (Cagrilintide + Semaglutide) reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
CagriSema (Cagrilintide + Semaglutide) — frequently asked by B2B buyers.
Is CagriSema supplied as one peptide or a blend?
It ships as a co-formulated blend of two separate peptides, cagrilintide and semaglutide, lyophilized together in a single vial. Because it is a two-API blend, there is no single CAS number or molecular weight; each component is identified and quantified independently on the COA.
What vial sizes, ratios and MOQ are available?
Standard research vials are offered at 5 mg and 20 mg total peptide, with a minimum order of 50 vials. The cagrilintide-to-semaglutide ratio can be specified per project; contact us for custom ratios or fill volumes.
What documentation ships with each lot?
Every lot includes a Certificate of Analysis reporting HPLC purity and mass-spectrometry (MS) identity for both components, plus appearance, peptide content, and residual water/solvent data. Independent third-party verification is available on request.
Can Pepti private-label or customize the fill?
Yes. As an OEM and private-label manufacturer we support custom vial labeling, box and blister packaging, blend-ratio adjustments, and bulk API supply. Send your artwork and specifications with the RFQ.
What is the compliance status of this material?
It is supplied strictly as a research-use, laboratory reference material for B2B buyers, not for human or veterinary use. The branded finished combination is an investigational drug under regulatory review; buyers are responsible for import, labeling, and end-use compliance in their own jurisdiction.
Related compounds